Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This Phase 3 trial is testing whether a new drug called SKB264 works better than standard chemotherapy as a first treatment for people with metastatic triple-negative breast cancer (TNBC) that has spread or come back. The study will enroll about 524 participants whose tumors do n…

This early-phase trial is testing an experimental drug called SKB445 in 126 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and get an early look at whether the drug can shrink tumors. Part…

This study tests an experimental drug called SKB518, given alone or with chemotherapy, in 280 people with advanced ovarian, cervical, or endometrial cancers. The goal is to see if the drug can shrink tumors or slow cancer growth. Researchers will also monitor side effects.

This phase 2 trial tests a new drug called SKB571 in 295 people with advanced non-small cell lung cancer. The goal is to see if the drug is safe and can shrink tumors. Participants receive the drug every three weeks until the disease gets worse or side effects become too severe.

This early-stage trial tests a new drug called SKB518 in 150 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants receive the drug every …

This early-phase study tests a new drug called SKB571 in 138 adults with advanced solid tumors that have spread. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Participants must have measurable tumors and be in fairly go…

This study tests a new drug called SKB105 in 256 adults with advanced solid tumors that have not responded to standard treatments. SKB105 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial will first find the safest dose, then check…

This early-stage trial is testing a new drug called SKB107, which delivers radiation directly to bone tumors. It is for people with advanced solid tumors (like breast, prostate, or lung cancer) that have spread to the bones and who have run out of standard treatment options. The …

This study tests whether adding the experimental drug SKB264 to the standard targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 420 adults who have not had prior treatment for advanced dis…

This study tests a new combination of drugs (SKB264 plus KL-A167, with or without chemotherapy) in about 110 adults with advanced or metastatic non-small cell lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow cancer growth. Participants must h…

This study tests whether a new drug, sacituzumab tirumotecan, given alone or with another drug (osimertinib), can shrink tumors before surgery in people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). About 60 adults aged 18-75 who have not had prio…

This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …

This study tests a new drug called SKB571 in 60 adults with advanced non-small cell lung cancer that has specific MET gene changes and has worsened after standard treatments. Participants receive SKB571 alone to see if it shrinks tumors and how safe it is. The goal is to control …

This early-phase study tests the safety and best dose of SKB315, a drug designed to attack cancer cells with a specific protein called Claudin18.2. About 246 adults with advanced solid tumors that haven't responded to standard treatments will receive the drug. The goal is to see …

This phase 3 study tests a new drug called SKB264 against standard chemotherapy in 376 people with advanced HR+/HER2- breast cancer that has not responded to at least one prior chemo. The goal is to see if SKB264 can slow cancer growth and improve survival. Participants are rando…

This study tests a new drug called A166 in people with HER2-positive breast cancer that has spread and no longer responds to certain previous treatments. About 40 adults aged 18 to 75 will receive A166 to see if it shrinks tumors or slows the disease. The goal is to find a better…

This study tests a new drug, SKB103, in people with advanced solid tumors who have run out of standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About 277 adults aged 18 to 75 will take part.

This study tests a new drug called SKB518 in 192 adults with lung cancer (non-small cell or small cell). The goal is to see if it shrinks tumors and to check for side effects. Participants receive the drug alone until their disease gets worse or side effects become too severe.

This study tests a new drug combination (SKB500) in 80 adults with small cell lung cancer, a fast-growing type of lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow the disease. Participants must be 18-75 and have extensive-stage cancer, with s…

This early-stage study tests a new drug called SKB500 in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and side effects, and to see if it can shrink tumors. Researchers will also measure how the d…

This study tests a new drug called SKB264 against standard chemotherapy in people with advanced hormone receptor-positive, HER2-negative breast cancer that has stopped responding to hormone therapy. About 430 adults aged 18-75 will be randomly assigned to receive either SKB264 or…

This study tests whether adding the experimental drug SKB264 to the immunotherapy pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with advanced non-squamous lung cancer that lacks the PD-L1 protein. About 432 adults with stage IIIB/IV disease w…

This early-stage study tests a new medicine called SKB575 in healthy volunteers and people with moderate to severe atopic dermatitis (eczema). The main goals are to check safety and how the body processes the drug. A small group of eczema patients will also be monitored for skin …